Table 3.
Secondary efficacy variable assessment across time in both the groups.
| Efficacy variables (Mean ± SD) |
Visits | Etodolac group (n = 30) |
Etodolac + eperisone group (n = 30) |
Difference between the groups (P value) |
|---|---|---|---|---|
| Joint tenderness score | Baseline At 8 weeks |
2.63 ± 0.49 1.43 ± 0.80 |
2.50 ± 0.51 1.07 ± 0.65 |
0.086 |
| Swelling score | Baseline At 8 weeks |
1.87 ± 0.68 1.07 ± 0.25 |
1.90 ± 0.84 1.00 ± 0.00 |
0.107 |
| Erythema score | Baseline At 8 weeks |
1.80 ± 0.66 1.07 ± 0.25 |
1.87 ± 0.82 1.03 ± 0.18 |
0.232 |
| Pain on movement score | Baseline At 8 weeks |
2.43 ± 0.57 1.23 ± 0.43 |
2.37 ± 0.56 1.03 ± 0.48 |
0.097 |
| Functional capacity score | Baseline At 8 weeks |
2.57 ± 0.57 1.27 ± 0.52 |
2.43 ± 0.50 1.10 ± 0.31 |
0.107 |
| Overall arthritic condition score | Baseline At 8 weeks |
3.53 ± 0.57 1.70 ± 0.70 |
3.47 ± 0.51 1.50 ± 0.57 |
0.135 |